Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

Educational information

This 3-minute education provides a summary of recently presented scientific data, recorded during the VBWG meeting at ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Eliot Brinton, MD, is Director of Atherometabolic Research at the Utah Foundation for Biomedical Research, and President of the Utah Lipid Center, in Salt Lake City, UT, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.